Browsing by Author "Ayensu, Isaac"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Bioavailability studies on a locally manufactured paracetamol tablet.
    (2002) Ayensu, Isaac
    Bioavailability studies using urinary excretory data have been carried out. Paracetamol tablets from a Ghanaian Pharmaceutical Manufacturing Company were adequately identified quantified and their pharmaceutical equivalence with respect to a reference established. The fraction of dose excreted unchanged in urine by the test and reference samples, and the Relative Bioavailability of the test sample was determined using a crossover design. 1 000mg each of the test and reference samples were administered to the subjects in a lasting state, with a washout period of one week between drug administrations. Urine samples were collected and analysed at specified time intervals, spanning 24 hours. The analytical method employed was RP-LC with a stationary phase of Spherisord S5ODS I Phase Sep column and a mobile phase combination of Methanol, Water nd Glacial Acetic Acid in the ratio: 2$: 69: 3 respectively. Column eluate was monitored at 236nm a U V detector. The analysis was conducted at an ambient temperature with a flow rate of l.5ml/min. and 0.5AUFS. The mean percentage amounts of paracetamol excreted unchanged in urine was found to be 10.521 % and 10.691% 1br the test and reference samples respectively. The Relative Bioavailability of the test sample was found to be 98.41 % which is within the WI l( range of 80% to 1 25%. The determined means and standard deviations were statistical l compared and found not to differ significantly. The test and reference samples were found to be pharmaceutically equivalent, Bioequivalent and therapeutically equivalent. They are therefore interchangeable for therapeutic purposes.
  • No Thumbnail Available
    Item
    Evaluation of acid neutralizing and buffering capacities of selected antacids in Ghana
    (Elsevier, 2020) Ayensu, Isaac; Bekoe, S. O.; Adu, J. K.; Brobbey, A. A.; Appiah, E.
    This study has evaluated the acid neutralizing and buffering capacities (BC) of nine selected antacid brands (“L1-L9”) in Ghana. The active acid neutralizing ingredients were recorded and the preliminary antacid test (PAT) determined with 0.5 N HCl after 10 min. The acid neutralizing capacity (ANC) was evaluated with 1 N HCl by neutralizing the excess with 0.5 N NaOH after 15 min stirring. Buffering capacity (BC) was estimated with 0.1 N HCl and titrated with 0.1 N NaOH at 5 min interval up to 50 min. All determination were at 37±3 °C using a pH meter. All brands had as part of their active ingredients dried aluminum hydroxide and magnesium hydroxide, with 67% containing simethicone as antifoam. The PAT declared all brands to be antacids with pH range of 4.38 ± 0.21– 6.43 ± 0.06. The ANC of all brands were in the range 13.16 ± 0.55–20.70 ± 0.18 mEq/g with “L4” and “L9” having the lowest and highest values respectively. “L9” further demonstrated a considerably higher BC up to 40 min whiles “L6” had the least BC up to 15 min. The ability of an antacid to have a high ANC and to resist significant changes in pH (longer BC) is crucial in assuring quality and efficacy of the brand.